Shots:

• The P-II (APEX) trial evaluated bezuclastinib in patients with AdvS. The updated data will be expected at the end of 2022
• As of the data cutoff date of May 2022, 11 patients were evaluated for signs of clinical activity, all patients achieved a ≥50% reduction in serum tryptase levels with a median reduction of 89% & 6 achieved a reduction to <20 ng/mL. All 8 bone marrow biopsy-assessed patients achieved ≥50% bone marrow mast cells reduction & 6 with complete clearance
• 8 patients showed a reduction in KIT D816V VAF, 3 discontinued avapritinib for toxicity reasons, clinical outcomes consistent with avapritinib-naïve patients, were well-tolerated with no reported periorbital or peripheral edema, cognitive effects, or intracranial bleeding events

Ref: Globenewswire | Image: Cogent